EUCTR2007-002132-29-GB进行中（未招募）不适用
A Phase II Trial of Sorafenib (a tyrosine kinase inhibitor) given orally twice daily in renal cancer patients with vHL syndrome - Oral Sorafenib in renal cancer patients with vHL syndrome
Oxford Radcliffe Hospitals NHS Trust0 个研究点目标入组 25 人开始时间: 2008年2月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible, a patient must meet all of the following criteria:
- •1.Proven von Hippel Lindau syndrome by clinical, genetic or histological criteria.
- •2.Aged greater than 18 years.
- •3.ECOG performance status of 0-2
- •4.Lesions will be treated at a size below which surgery would be contemplated in order to prevent progression to larger lesions. Patients must have:
- •either a) Multiple renal lesions likely to lead to renal surgery. Lesions must be less than or equal to 2.4cm; OR b) Evidence on serial MRI scans for development of new lesions or progression of existing lesions. Note: other common sites of disease will be assessed by appropriate methodology at baseline (e.g. eyes – fluorescence angiography, Central Nervous System (brain/spinal cord) – MRI).
- •5.All patients must be using effective contraception. Women who are pregnant, nursing, or planning pregnancy within 6 months after the last treatment may not be included in the study (this includes men who plan to father a child within 6 months of the last treatment). Women of childbearing potential and all men who are (or become) sexually active must use adequate birth control measures (e.g. oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) throughout the study and must continue such precautions for 6 months after receiving the last study agent infusion. All women of child-bearing age (i.e. unless postmenopausal, having had no menstrual period >=1 yr) must have a negative serum or urine pregnancy test performed within 7 days before the start of treatment.
- •6.Patient must give written, informed consent.
- •7.Haematological and biochemical indices within the following ranges (tests performed within one week before the patient goes on study) : Haemoglobin >or= 9.0 g/dl ; Platelet count > or =100 x 10 to the power of 9/L; Absolute Neutrophil count >or =1.5 x 10 to the power of 9/L; Serum bilirubin < or =1.5 x upper normal limit; Alanine amino-transferase (ALT) < or =2.5 x upper limit of normal (ULN) unless due to tumour in which case up to 5 x ULN is permissible; and Creatinine < or =180 µmol/L
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A patient will not be eligible for the trial if any of the following criteria apply:
- •1.Radiotherapy (except for palliative reasons), major surgery, endocrine therapy, immunotherapy, chemotherapy or experimental therapy during four weeks (six weeks for nitrosureas and Mitomycin-C) prior to starting or during trial treatment.
- •2.Has had a myocardial infarction in the past twelve months, severe or unstable angina. Patients with a history of atherosclerotic coronary artery disease requiring coronary or peripheral artery bypass surgery may only be enrolled provided the surgery occurred at least two years prior to enrolment and after consultation with a cardiologist to ensure that the disease is stable.
- •3.Concurrent congestive heart failure or prior history of class III/ IV cardiac disease (New York Heart Association [NYHA. Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted.
- •4.Uncontrolled hypertension, defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management.
- •5.Haemorrhage or bleeding event >CTCAE Grade 2 within 4 weeks prior to start of study drug. Taking therapeutic anticoagulation with vitamin K antagonists such as warfarin, or with heparins or heparinoids. Low dose warfarin (1 mg po qd) is permitted if the INR (International normalized ratio) is <=1.5. Low-dose aspirin permitted (<= 75 mg daily).
- •6.Has insulin-dependent diabetes mellitus, or has non-insulin dependent diabetes mellitus with clinical evidence of severe peripheral vascular disease or diabetic ulcers.
- •7.High medical risk due to active uncontrolled infection (> grade 2 NCI-CTCAE (National Cancer Institute Common Terminology for adverse Events) version 3.0) or non-malignant systemic disease (> grade 2 NCI-CTCAE version 3.0).
- •8.Co-existing or previous other malignancies unless in complete remission for not less than 5 years & excepting in situ carcinoma of the cervix or basal cell skin carcinoma.
- •9.History of HIV (Human immunodeficiency virus) infection or chronic hepatitis B or C.
- •10.Inability to swallow oral medication.
- •11.Known or suspected allergy to sorafenib or its constituents.
- •12.Other psychological, social or medical condition or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results.
研究者
相似试验
进行中（未招募）
1 期
A randomized phase II trial assessing Sorafenib (Nexavar®) in combination with irinotecan in metastatic colorectal cancer patients with KRAS mutated tumours after failure of all active drugs known to be effective. - NEXIRI 2metastatic colorectal cancerMedDRA version: 16.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2012-000644-94-FRCentre Val d’Aurelle - Paul Lamarque159
招募中
2 期
Phase II study of sorafenib-regorafneib sequential therapy for the patients with advanced hepatocellular carcinoma previously treated with lenvatinibHepatocellular carcinomaJPRN-jRCT1041190082Yamashita Tatsuya33
Unknown
1 期
Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast CancerMetastatic Breast CancerNCT00764972McGill University36
进行中（未招募）
1 期
A Phase 2 study of Sorafenib (BAY 43-9006) in patients with advanced salivary Adenoid Cystic CarcinomaEUCTR2008-000066-22-GBChristie Hospital NHS Foundation Trust
进行中（未招募）
不适用
Phase II single agent sorafenib in the treatment of relapsed oesophageal/gastric adenocarcinoma in platinum pre-treated patients - Sorafenib upper GI studyEUCTR2008-005062-31-IEICORG, the all-Ireland Co-operative Oncology Research Group54